Study of the Fimasartan effects on cardiovascular events and metabolic syndrome in patients with hypertensio
Not Applicable
Completed
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0000529
- Lead Sponsor
- Cheil General Hospital & Women's healthcare center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20000
Inclusion Criteria
1.Patients with hypertension who are 20 years old and higher and need angiotensin ? receptor blockers(ARBs), Fimasartan(Kanarb)
2.Patients who agreed to this study and handed out written consent forms
3.Patients who visited after fasting
Exclusion Criteria
1. Patients who are currently taking Kanarb
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the frequency and incidence of major adverse cardiovascular event(MACE) in the treated kanarb during average 3 years of follow-up visits using a cohort study with office hypertension
- Secondary Outcome Measures
Name Time Method Changes in degree of metabolic risk after 3 months of follow-up observation.;A incidence of metabolic syndrome and diabetes after 1-year follow-up ;Effect of blood pressure changes and side effects according to presence or absence of metabolic syndrome;Difference of clinic and home blood pressure after Kanarb treatment;changes of incidence of white coat and masked hypertension after Kanarb treatment;Changes of blood pressure variability after Kanarb treatment